Zobrazeno 1 - 10
of 342
pro vyhledávání: '"Sreekumar, G."'
Publikováno v:
In Chemical Engineering Science 12 October 2022 260
Autor:
Jonathan I. Silverberg, Emma Guttman-Yassky, Diamant Thaçi, Alan D. Irvine, Linda Stein Gold, Andrew Blauvelt, Eric L. Simpson, Chia-Yu Chu, Zhuqing Liu, Renata Gontijo Lima, Sreekumar G. Pillai, Julien Seneschal
Publikováno v:
New England Journal of Medicine. 388:1080-1091
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a922707fe1bf956d4d00a993871ea407
https://doi.org/10.1056/nejmoa2206714
https://doi.org/10.1056/nejmoa2206714
Publikováno v:
In Procedia Computer Science 2018 143:277-284
Publikováno v:
Reviews on Advanced Materials Science, Vol 53, Iss 1, Pp 29-39 (2018)
Collagen, a biopolymer finds its application in the preparation of pharmaceutical products that are used in wound management, ophthalmic, orthopaedic and oral surgeries. This wide applicability is due its special properties such as biodegradability,
Externí odkaz:
https://doaj.org/article/a64b2ce6c4a54478b0a995b4322742b9
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Laura C, Coates, Sreekumar G, Pillai, Hasan, Tahir, Ivo, Valter, Vinod, Chandran, Hideto, Kameda, Masato, Okada, Lisa, Kerr, Denise, Alves, So Young, Park, David H, Adams, Gaia, Gallo, Matthew M, Hufford, Maja, Hojnik, Philip J, Mease, Arthur, Kavanaugh, Hana, Zelenkova
Publikováno v:
Arthritis & Rheumatology (Hoboken, N.j.)
Objective To evaluate the effect of withdrawing ixekizumab in patients with psoriatic arthritis (PsA) in whom minimal disease activity (MDA) has been achieved after open-label ixekizumab treatment. Methods SPIRIT-P3 was a multicenter, randomized, dou
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ae56f2b60b94c6636f76133331dfedd
https://doi.org/10.1002/art.41716
https://doi.org/10.1002/art.41716
Autor:
Lingnan Li, Paulo Reis, Inmaculada de la Torre, Amanda M. Gellett, Hendrik Schulze-Koops, Anthony Sebba, Soyi Liu-Leage, Josef S Smolen, Gaia Gallo, Peter Nash, Eric Ruderman, Christophe Sapin, Aubrey Trevelin Sprabery, Sreekumar G. Pillai
Publikováno v:
Rheumatology and Therapy
Introduction In the SPIRIT-H2H (ClinicalTrials.gov: NCT03151551) trial in biologic-naïve patients with active psoriatic arthritis (PsA), ixekizumab (IXE) was superior to adalimumab (ADA) at week 24 in terms of achieving a combined endpoint of ≥ 50
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::79c326750bf79fdba78d0617c1bc953f
https://doi.org/10.1007/s40744-020-00250-3
https://doi.org/10.1007/s40744-020-00250-3
Autor:
Hendrik Schulze-Koops, Josef S Smolen, Jordi Gratacós, Roberto Caporali, Lingnan Li, Sreekumar G. Pillai, Peter Nash, Masato Okada, Philip J. Mease, Christophe Sapin, Hasan Tahir, Inmaculada de la Torre, M. Hojnik, Philippe Goupille, Soyi Liu Leage
Publikováno v:
Annals of the Rheumatic Diseases
ObjectivesSPIRIT head-to-head (H2H) is a 52-week (Wk) trial comparing ixekizumab (IXE) with adalimumab (ADA) for simultaneous American College of Rheumatology (ACR)50 and Psoriasis Area and Severity Index (PASI)100 responses in 566 patients (distribu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c8d161bb07dd4f052ecb8484fa2e0369
https://doi.org/10.1136/annrheumdis-2020-217372
https://doi.org/10.1136/annrheumdis-2020-217372
Autor:
Sreekumar, G., Louie Frobel, P.G., Sreeja, S., Suresh, S.R., Mayadevi, S., Muneera, C.I., Suchand Sandeep, C.S., Philip, Reji, Mukharjee, Chandrachur
Publikováno v:
In Chemical Physics Letters 11 April 2011 506(1-3):61-65
Autor:
Guoqing Wang, Rui Wang, Yael Strulovici-Barel, Jacqueline Salit, Michelle R Staudt, Joumana Ahmed, Ann E Tilley, Jenny Yee-Levin, Charleen Hollmann, Ben-Gary Harvey, Robert J Kaner, Jason G Mezey, Sriram Sridhar, Sreekumar G Pillai, Holly Hilton, Gerhard Wolff, Hans Bitter, Sudha Visvanathan, Jay S Fine, Christopher S Stevenson, Ronald G Crystal
Publikováno v:
PLoS ONE, Vol 10, Iss 4, p e0120824 (2015)
Even after quitting smoking, the risk of the development of chronic obstructive pulmonary disease (COPD) and lung cancer remains significantly higher compared to healthy nonsmokers. Based on the knowledge that COPD and most lung cancers start in the
Externí odkaz:
https://doaj.org/article/1b6f44e9a64d47daab4df117cf0df208